Halozyme Therapeutic (HALO)

$66.98 -0.84 (-1.24%)
Market Cap 8.03B
Revenue (ttm) 1.40B
Net Income (ttm) 316.89M
EPS (ttm) N/A
PE Ratio 17.75
Forward PE 8.72
Profit Margin 22.69%
Debt to Equity Ratio 43.90
Volume 1,042,800
Avg Vol 1,804,444
Day's Range N/A - N/A
Shares Out 118.47M
Stochastic %K 79%
Beta 1.03
Analysts Sell
Price Target $82.50

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md Apr. 7 at 6:16 PM
$HALO From Morgan Stanley today: “ We view this announcement as strategically important, as it further validates Hypercon as a next‑generation drug delivery platform capable of enabling high‑concentration, small‑volume biologics suitable for at‑home administration, while also reinforcing Halozyme’s broader evolution beyond ENHANZE. Importantly, the partnership aligns with our long‑term thesis that Hypercon and SurfBio technologies can meaningfully extend Halozyme’s royalty growth profile well beyond the 2030s, helping to mitigate the anticipated ENHANZE royalty cliff. The addition of a blue‑chip partner like Vertex meaningfully de‑risks this strategy by increasing confidence in both technical adoption and eventual commercial translation of Hypercon‑enabled products. We see the deal as a positive signal for the durability and scalability of Halozyme’s post‑ENHANZE growth engine and an incremental step toward sustaining long‑duration, high‑quality royalty streams over the next decade.
0 · Reply
solanolon
solanolon Apr. 7 at 1:15 PM
The market is reacting positively because $HALO walking away from the Evotec bid looks like discipline, not weakness. Sometimes the best deal is the one you do not force.
0 · Reply
Sean29md
Sean29md Apr. 7 at 12:50 PM
$HALO Hypercon is bearing fruit for Halozyme immediately. The new partner, Vertex, is a large cap (over $100 billion) biopharma company with multiple approved products. Well done Helen! This is a stark contrast to Antares which after nearly 4 years has still not produced a single HVAI commercial contract. I think if Helen could go back she would not have purchased Antares. Not to mention we inherited such subpar IR leadership through that acquisition.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 7 at 12:08 PM
$HALO $VRTX Halozyme enters global global collaboration and license agreement with Vertex Halozyme (HALO) announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (VRTX). Under the collaboration, Vertex has licensed Halozyme's Hypercon technology for use in up to three drug targets. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. Under the terms of the exclusive agreement, Vertex will make a $15M upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon technology.
0 · Reply
TheTradeXchange
TheTradeXchange Apr. 7 at 12:03 PM
$HALO - Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
0 · Reply
Sean29md
Sean29md Apr. 6 at 3:28 PM
$HALO
0 · Reply
Sean29md
Sean29md Apr. 5 at 7:52 PM
$HALO Below is the link to a summary of Halozyme’s arguments for its motion to terminate Merck’s PGR’s. Given everything in these decks plus the procedural history we’ve tracked: 65-70% probability of termination. -The prior KEYTRUDA IPR RPI listings are quite damaging for Merck. Merck’s own litigation counsel — Jeffrey Kushan of Sidley Austin, the same lead counsel here — listed MCI as RPI in nine prior KEYTRUDA proceedings. -The legal authority hierarchy favors Halozyme. Post-AIT Federal Circuit standard plus fresh Yangtze Memory informative designation versus mostly pre-2018 PTAB panel decisions on Merck’s side. PTAB doesn’t need perfection—just enough to conclude: “This looks like a real party in interest under a practical test.” https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00003%2F2501
0 · Reply
Pittsburgh21
Pittsburgh21 Apr. 3 at 4:01 PM
$HALO Is the recent huge sale by HALO executives a signal that something may be happening?
1 · Reply
Sean29md
Sean29md Mar. 31 at 3:12 PM
$HALO time for Helen, C-suite and BOD to wake up! Halozyme has severely underperformed its peers in XBI and IBB (see attached 1 month, 6 months and one year charts). With a gross profit margin greater than 70%, EPS CAGR of +30%, Halozyme should not be trading at a 2026 PE ratio of 8 and PEG ratio of 0.25. You are failing to attract the right mix of investors. How long before you wake up this fact? Helen needs to be on investment podcasts, youtube, CNBC and Bloomberg.
0 · Reply
Doozio
Doozio Mar. 31 at 2:05 PM
Roger shall rock his $HALO and da 🧠 shall $EXEL again out of the tightness.
0 · Reply
Latest News on HALO
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Apr 7, 2026, 8:00 AM EDT - 7 days ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Mar 12, 2026, 8:30 AM EDT - 4 weeks ago

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Mar 6, 2026, 8:00 AM EST - 5 weeks ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 6 weeks ago

Halozyme to Participate in Upcoming Investor Conferences

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 17, 2026, 4:01 PM EST - 7 weeks ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 4:05 PM EST - 2 months ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 2 months ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 2 months ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 3 months ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 3 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 4 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 4 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 4 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 4 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 4 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 5 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 5 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 5 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 5 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 5 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 5 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 5 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 6 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 6 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 6 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 6 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 8 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 8 months ago

Halozyme to Participate at Upcoming Investor Conferences

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 8 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 9 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 9 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 10 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 10 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 11 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 1 year ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 1 year ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 6:15 PM EDT - 1 year ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 9, 2025, 8:45 AM EDT - 1 year ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Apr 7, 2025, 9:29 AM EDT - 1 year ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 1 year ago

Halozyme Joins the $1 Billion Club

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:30 AM EST - 1 year ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 18, 2025, 4:01 PM EST - 1 year ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 4, 2025, 8:30 AM EST - 1 year ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Feb 3, 2025, 7:30 AM EST - 1 year ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Jan 8, 2025, 7:00 AM EST - 1 year ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Jan 6, 2025, 8:30 AM EST - 1 year ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Sean29md
Sean29md Apr. 7 at 6:16 PM
$HALO From Morgan Stanley today: “ We view this announcement as strategically important, as it further validates Hypercon as a next‑generation drug delivery platform capable of enabling high‑concentration, small‑volume biologics suitable for at‑home administration, while also reinforcing Halozyme’s broader evolution beyond ENHANZE. Importantly, the partnership aligns with our long‑term thesis that Hypercon and SurfBio technologies can meaningfully extend Halozyme’s royalty growth profile well beyond the 2030s, helping to mitigate the anticipated ENHANZE royalty cliff. The addition of a blue‑chip partner like Vertex meaningfully de‑risks this strategy by increasing confidence in both technical adoption and eventual commercial translation of Hypercon‑enabled products. We see the deal as a positive signal for the durability and scalability of Halozyme’s post‑ENHANZE growth engine and an incremental step toward sustaining long‑duration, high‑quality royalty streams over the next decade.
0 · Reply
solanolon
solanolon Apr. 7 at 1:15 PM
The market is reacting positively because $HALO walking away from the Evotec bid looks like discipline, not weakness. Sometimes the best deal is the one you do not force.
0 · Reply
Sean29md
Sean29md Apr. 7 at 12:50 PM
$HALO Hypercon is bearing fruit for Halozyme immediately. The new partner, Vertex, is a large cap (over $100 billion) biopharma company with multiple approved products. Well done Helen! This is a stark contrast to Antares which after nearly 4 years has still not produced a single HVAI commercial contract. I think if Helen could go back she would not have purchased Antares. Not to mention we inherited such subpar IR leadership through that acquisition.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 7 at 12:08 PM
$HALO $VRTX Halozyme enters global global collaboration and license agreement with Vertex Halozyme (HALO) announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (VRTX). Under the collaboration, Vertex has licensed Halozyme's Hypercon technology for use in up to three drug targets. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. Under the terms of the exclusive agreement, Vertex will make a $15M upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon technology.
0 · Reply
TheTradeXchange
TheTradeXchange Apr. 7 at 12:03 PM
$HALO - Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
0 · Reply
Sean29md
Sean29md Apr. 6 at 3:28 PM
$HALO
0 · Reply
Sean29md
Sean29md Apr. 5 at 7:52 PM
$HALO Below is the link to a summary of Halozyme’s arguments for its motion to terminate Merck’s PGR’s. Given everything in these decks plus the procedural history we’ve tracked: 65-70% probability of termination. -The prior KEYTRUDA IPR RPI listings are quite damaging for Merck. Merck’s own litigation counsel — Jeffrey Kushan of Sidley Austin, the same lead counsel here — listed MCI as RPI in nine prior KEYTRUDA proceedings. -The legal authority hierarchy favors Halozyme. Post-AIT Federal Circuit standard plus fresh Yangtze Memory informative designation versus mostly pre-2018 PTAB panel decisions on Merck’s side. PTAB doesn’t need perfection—just enough to conclude: “This looks like a real party in interest under a practical test.” https://s3-us-west-1.amazonaws.com/ptab-filings%2FPGR2025-00003%2F2501
0 · Reply
Pittsburgh21
Pittsburgh21 Apr. 3 at 4:01 PM
$HALO Is the recent huge sale by HALO executives a signal that something may be happening?
1 · Reply
Sean29md
Sean29md Mar. 31 at 3:12 PM
$HALO time for Helen, C-suite and BOD to wake up! Halozyme has severely underperformed its peers in XBI and IBB (see attached 1 month, 6 months and one year charts). With a gross profit margin greater than 70%, EPS CAGR of +30%, Halozyme should not be trading at a 2026 PE ratio of 8 and PEG ratio of 0.25. You are failing to attract the right mix of investors. How long before you wake up this fact? Helen needs to be on investment podcasts, youtube, CNBC and Bloomberg.
0 · Reply
Doozio
Doozio Mar. 31 at 2:05 PM
Roger shall rock his $HALO and da 🧠 shall $EXEL again out of the tightness.
0 · Reply
Makingmillions192
Makingmillions192 Mar. 30 at 6:53 PM
$LEXX Relative comps for Lexaria. Halozyme Therapeutics ($HALO ): $7.3 Billion. The industry leader in drug delivery. They use their ENHANZE platform to help Big Pharma turn intravenous drugs into simple subcutaneous injections. Sounds similar to Lexaria but we are doing that orally for any peptide 👀 👆👆👆 • Provention Bio ($PRVB): $2.9 Billion (Acquired). Focused on intercepting and preventing immune-mediated diseases. They were acquired by Sanofi in 2023 for approximately $2.9 billion to bolster their diabetes and immunology pipeline. • Rani Therapeutics ($RANI): $111 Million. Developers of the "RaniPill," a robotic capsule intended to replace injections by delivering large molecules (like GLP-1s) directly into the intestinal wall.
0 · Reply
Doozio
Doozio Mar. 26 at 6:18 PM
$XBI as da $HALO goes 3wt bahhhhtom of da base. 🐒🍌🧠⏰♾️
0 · Reply
Sean29md
Sean29md Mar. 25 at 11:29 PM
$HALO The two IV meds that biogen would like to convert to SC are most likley Tysabri (for MS) and Briumvi (for relapsing MS). Halozyme already had an exclusive contract with Roche on Ocrevus (for MS) and could not have made a deal with Biogen for the same class of meds. The right thing to do for Biogen is to pay MDASE royalties to Halozyme and just pay Alteogen for manufacturing. But don’t worry, right after Merck is compelled by courts to sign an MDASE licensing deal with Halozyme for Keytruda SC or pay triple damages, Biogen will get in line for MDASE as well.
1 · Reply
Sean29md
Sean29md Mar. 25 at 8:05 PM
$HALO hey Helen, C-suite and Halozyme BOD, wake up! Alteogen just signed another partnership with big pharma. What’s the matter with you? Where are your Enhanze, HVAI and hypercon deals? https://www.fiercepharma.com/pharma/biogen-pays-20m-upfront-tap-alteogens-subq-delivery-tech
0 · Reply
Sean29md
Sean29md Mar. 24 at 7:15 PM
$HALO Halozyme 2026 Non-GAAP Diluted EPS $7.75-$8.25, a 87-99% Growth compared to 2025 (see attached screen shot)! This offered at a 2026 PE ratio of 8.13 and PEG of 0.25 (see link) https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
0 · Reply
Doozio
Doozio Mar. 24 at 7:08 PM
If da $HALO is gonna protect da 🧠 on da $DLO it’s 3wt bahhhtom of da base chop chop huckleberries 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Mar. 23 at 9:20 PM
$XBI needs a $HALO to protect yo n $ASND
1 · Reply
Doozio
Doozio Mar. 23 at 6:06 PM
$AUPH MNDY 🐑 term suck in or a 🐑 shake on da $HALO ?
0 · Reply
ISmokeMoney
ISmokeMoney Mar. 18 at 10:31 PM
$HALO $58 by Friday
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 17 at 8:44 PM
$HALO Share Price: $65.13 Contract Selected: Sep 18, 2026 $65 Calls Buy Zone: $5.02 – $6.20 Target Zone: $9.34 – $11.42 Potential Upside: 76% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
draketdot
draketdot Mar. 17 at 4:28 AM
$HALO back to ath. Wedge formed. Give it 1-2months
1 · Reply
Sean29md
Sean29md Mar. 16 at 9:50 PM
$HALO https://www.press9.kr/news/articleView.html?idxno=73491#:~:text=According%20to%20court%20filings%2C%20Halozyme,play%20a%20critical%20role%20in
0 · Reply